Newamsterdam pharma announces positive topline data from pivotal phase 3 broadway clinical trial evaluating obicetrapib in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia

-- achieved primary endpoint of ls mean reduction vs placebo in ldl-c on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p
NAMS Ratings Summary
NAMS Quant Ranking